Estrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes

Yasumasa Ikeda¹, Soichiro Tajima¹, Yuki Izawa-Ishizawa¹, Yoshitaka Kihira¹, Keisuke Ishizawa², Shuhei Tomita¹, Koichiro Tsuchiya², Toshiaki Tamaki¹

¹ Department of Pharmacology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, ² Department of Medical Pharmacology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan

Abstract

Hepcidin, a liver-derived iron regulatory protein, plays a crucial role in iron metabolism. It is known that gender differences exist with respect to iron storage in the body; however, the effects of sex steroid hormones on iron metabolism are not completely understood. We focused on the effects of the female sex hormone estrogen on hepcidin expression. First, ovariectomized (OVX) and sham-operated mice were employed to investigate the effects of estrogen on hepcidin expression in an in vivo study. Hepcidin expression was decreased in the livers of OVX mice compared to the sham-operated mice. In OVX mice, bone morphologic protein-6 (BMP6), a regulator of hepcidin, was also found to be downregulated in the liver, whereas ferroportin (FPN), an iron export protein, was upregulated in the duodenum. Both serum and liver iron concentrations were elevated in OVX mice relative to their concentrations in sham-operated mice. In in vitro studies, 17β-estradiol (E₂) increased the mRNA expression of hepcidin in HepG2 cells in a concentration-dependent manner. E₂-induced hepatic hepcidin upregulation was not inhibited by ICI 182720, an inhibitor of the estrogen receptor; instead, hepcidin expression was increased by ICI 182720. E₂ and ICI 182720 exhibit agonist actions with G-protein coupled receptor 30 (GPR30), the 7-transmembrane estrogen receptor. G1, a GPR30 agonist, upregulated hepcidin expression, and GPR30 siRNA treatment abolished E₂-induced hepcidin expression. BMP6 expression induced by E₂ was abolished by GPR30 silencing. Finally, both E₂ and G1 supplementation restored reduced hepatic hepcidin and BMP6 expression and reversed the augmentation of duodenal FPN expression in the OVX mice. In contrast, serum hepcidin was elevated in OVX mice, which was reversed in these mice with E₂ and G1. Thus, estrogen is involved in hepcidin expression via a GPR30-BMP6-dependent mechanism, providing new insight into the role of estrogen in iron metabolism.

Introduction

Iron is an essential trace element that is necessary for all living cells and organisms. Approximately 3–5 g of iron is stored by healthy adults, and the amount of stored iron varies during the lifetime. It is well known that gender differences exist with respect to iron storage. Women exhibit low levels of iron storage from adolescence to menopause. In perimenopausal women, iron levels in the body increase to levels similar to those in men of the same age [1]. Lower iron storage levels in women is simply believed to be associated with blood loss during menstruation, which explains the increase in iron storage by women during perimenopause [2].

Menopause is detrimental for middle-aged and older women because of various so-called menopausal disorders. Menopause is generally considered to occur because of a deficiency in the female sex steroid hormone estrogen. In women, estrogen levels increase around adolescence and remain constant until perimenopause, when its levels decrease because of the cessation of ovarian function in the postmenopausal period. In terms of the relationship between iron and estrogen, it has been observed that there is a coincidental and inverse correlation between estrogen levels and iron storage during perimenopause [2]. Recently, several studies have demonstrated that estrogen exerts various effects on multiple organs, including both classical target organs and non-classical target organs [3]. We hypothesized that the reduction of estrogen levels due to menopause is responsible for increased iron accumulation due to changes in iron regulation. However, the effects of estrogen on iron regulation remain unknown.

Hepcidin is a secreted protein derived from hepatocytes, and it has been identified as an important regulator of iron metabolism [4]. Indeed, hepcidin has been demonstrated to regulate iron absorption in the duodenum through internalization and degradation of ferroportin (FPN), an exporter of iron [5]. In the present study, we demonstrate a new effect of estrogen on iron metabolism. Estrogen regulates hepcidin expression via G-coupled protein 30 (GPR30)–bone morphologic protein 6 (BMP6)-dependent signaling, indicating that estrogen actually decreases iron absorption in the intestine.


Results

Effect of Estrogen on Hepcidin Expression and Iron Absorption in vivo

To elucidate the effect of estrogen on iron metabolism in vivo, we compared hepatic iron and iron levels between OVX and sham-operated mice. Both mRNA and protein expression of hepcidin was significantly reduced in the livers of OVX mice as compared to the expression in the livers of sham-operated mice. Furthermore, the mRNA and protein levels of BMP6, an upstream regulator of hepcidin [6,7], were also decreased in the OVX mice as compared to those in the sham-operated mice (Figure 1A). Hepcidin is regulated by various factors, including inflammation and cytokines such as interleukin-6 (IL-6) [9]. We examined IL-6 expression in the liver. There were no differences in hepatic IL-6 expression between the sham-operated and OVX mice (data not shown).

Next, we evaluated the expression of FPN in the duodenum. As shown in Figure 1B, the protein level of duodenal FPN was significantly increased at 3 months after ovariectomy in the OVX mice. Similarly, immunohistochemical analysis showed increased FPN expression in the duodenum of OVX mice as compared to that in the duodenum of sham-operated mice (Figures 1C); moreover, changes in FPN localization were observed. In sham-operated mice, duodenal FPN expression was mostly localized around the nuclei in basement villous enterocytes, meanwhile, FPN expression in OVX mice was diffuse in cytoplasmic villous enterocytes (Figure 1D). Serum and liver iron levels were significantly elevated in the OVX mice as compared to those in the sham-operated mice (Figure 1E).

Effect of Estrogen on Hepcidin Expression in HepG2 and HuH-7 Cells

For further clarification, we examined the effects of estrogen on hepcidin expression in vitro using HepG2 cells. As shown in Figure 2A, E2 upregulated hepcidin mRNA expression in a concentration-dependent manner. The ER inhibitor ICI 182780 was used to determine whether the effects of estrogen on hepcidin were mediated by an ER-dependent pathway. Interestingly, ICI 182780 co-treatment increased hepcidin expression in both HepG2 (Figure 2B) and HuH-7 cells (Figure 2C).

E2 Induced Hepcidin Expression via GRP30-BMP6-mediated Signaling

GRP30 has been identified as a membrane receptor for estrogen [9], and several studies have shown that ICI 182780 exerts its effects as an agonist of GRP30 [10]. To determine whether E2 augments hepcidin expression through a GRP30-dependent pathway, we performed silencing experiments using siRNA against GRP30. The mRNA levels of GRP30 were decreased by 68% after treatment with GRP30 siRNA as compared to the levels in the control siRNA-treated cells (Figure 3A). GRP30 silencing suppressed E2-induced hepcidin expression almost entirely (Figure 3B). Similarly, silencing of GRP30 suppressed ICI 182780-induced hepcidin expression (Figure 3C). Moreover, the GRP30 agonist G1 stimulated hepcidin expression in a concentration-dependent manner (Figure 3D). Similar to hepcidin, BMP6 expression was stimulated by E2, ICI 182780, and G1 (Figure 4A). Moreover, E2-induced BMP6 upregulation was inhibited by GRP30 silencing in HepG2 cells (Figure 4B). To assess whether E2 induced hepcidin expression through BMP6 signaling, we used siRNA against BMP6. BMP6 expression was decreased by 78% after siRNA transfection (Figure 4C left). Silencing of BMP6 itself markedly decreased hepcidin expression, and E2-induced hepcidin upregulation was abolished by BMP6 silencing in HepG2 cells (Figure 4C right).

Effect of E2 or G1 Supplementation on the Repression of Hepcidin and BMP Expression in the Liver and Augmentation of FPN Expression in the Duodenum of OVX Mice

We investigated whether reduced hepcidin expression in the OVX mouse was restored by E2 or G1 supplementation. Administration of either E2 or G1 recovered hepcidin and BMP6 expression in the livers of OVX mice (Figure 5). Moreover, the increased FPN protein expression in the duodenum of the OVX mice was diminished by E2 or G1 treatment (Figure 6A), which was confirmed immunohistochemically (Figure 6B). The expression pattern of FPN in the villous enterocytes of the OVX mice was changed from diffuse to localized by E2 or G1 administration (left side of Figure 6B). Serum and liver iron concentrations were increased in the OVX mice, which was restored in the OVX mice with E2 and G1 administration (Figure 6C and D). In contrast to liver hepcidin expression, serum hepcidin levels were elevated in the OVX mice compared to the sham-operated mice, while the OVX-induced serum hepcidin increase was reduced by E2 or G1 treatment (Figure 6E).

Discussion

In the present study, we found that hepatic hepcidin expression was downregulated in OVX mice. Consequently, duodenal FPN expression was upregulated. Estrogen played a role in hepatic hepcidin expression in a GRP30-BMP6-dependent manner in vivo. These findings indicate that estrogen is involved in iron metabolism through the regulation of hepcidin.

Hepcidin, an antimicrobial peptide, is mainly produced and secreted by hepatocytes [11,12]. FPN, an iron exporter, also plays a pivotal role in intestinal iron absorption [13]. Recently, hepcidin was demonstrated to play a crucial role in iron metabolism by regulating iron absorption in the duodenum via FPN [5]. Indeed, hepcidin-deficient mice showed massive iron overload [14] and increased FPN expression in the duodenum [15]. Thus, the coordinated regulation of hepcidin and FPN is directly linked to duodenal iron absorption. In the present study, OVX mice showed decreased expression of hepatic hepcidin as compared to its expression in sham-operated mice, and E2 stimulated hepcidin expression in cultured hepatocytes. These data suggest that estrogen directly participates in the regulation of hepatic hepcidin expression. Indeed, the expression levels of FPN in the duodenum were also augmented in the OVX mice with reduced hepcidin expression, suggesting that accelerated iron absorption and consequent increased iron storage occur in the estrogen-deficient state. In fact, OVX mice showed augmented iron storage in the present study. Estrogen participates in iron metabolism via hepcidin and FPN, which is a new explanation for the increase in iron storage in women during menopause.

Hepcidin expression is regulated by various factors, and BMP6 regulates iron metabolism via hepatic hepcidin [6,7]. In the present study, BMP6 expression was significantly decreased in the livers of OVX mice as compared to that in the livers of sham-operated mice. In HepG2 cells, E2 treatment induced BMP6 expression in addition to hepcidin expression. BMP6 silencing abolished hepcidin expression, and E2 failed to upregulate hepcidin expression in HepG2 cells after BMP6 silencing. Moreover, E2-induced hepcidin expression as well as BMP6 expression was not suppressed by the ER antagonist ICI 182780. Unexpectedly, ICI 182780 augmented both hepcidin and
Figure 1. Effect of estrogen deprivation via an ovariectomy on hepcidin expression and iron absorption \textit{in vivo}. The expression of hepcidin (A) and bone morphological protein (BMP6) (B) was reduced in the livers of the OVX mice. The expression of hepcidin and BMP6 in liver...
BMP6 expression. ICI 182780 has been demonstrated to have an agonistic effect on GPR30, a membrane receptor for estrogen [9,10]. The GPR30 agonist G1 also upregulated the expression of hepcidin and BMP6; conversely, GPR30 silencing suppressed both E2- and ICI 182780-induced hepcidin and BMP6 expression. Finally, hepcidin expression in the livers of OVX female mice was recovered by E2 and G1 supplementation. These findings suggest that a GPR30-BMP6 pathway, not the classical ER-mediated signaling pathway, is involved in the E2-induced expression of hepcidin in the liver.

We also measured serum hepcidin concentrations, which were elevated in the OVX mice compared to sham-operated mice; the increased serum hepcidin levels in the OVX mice were suppressed compared to the levels in sham-operated mice by E2 or G1 administration. These results were unexpected and in contrast with the findings of hepatic hepcidin expression. There are several plausible explanations for these data. First, elevated serum hepcidin levels may be a compensatory consequence of upregulated FPN expression in the OVX mice. Berki and colleagues have shown that obese patients or those with diabetes or nonalcoholic steatohepatitis showed reduced hepatic hepcidin expression and increased adipose hepcidin expression compared to lean controls [16], which suggests that serum hepcidin is derived from not only the liver but also from other tissues including adipose. Second, hepcidin expression was reduced in the OVX mice, although tissues at 3 months after the sham operation or ovariectomy was analyzed. The expression values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=6–10 in each group. (C) The expression of ferroportin (FPN) was augmented in the duodena of the OVX mice. The protein expression of FPN in duodenal tissues at 3 months after the sham operation or ovariectomy was analyzed. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=6 in each group. (D) Immunohistochemical analysis of FPN expression in the duodena of sham-operated mice (upper) and OVX mice (lower). (E) Serum (µg dL⁻¹) and hepatic (ng g⁻¹) iron concentrations in sham-operated and OVX mice. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=8–12 in each group.

doi:10.1371/journal.pone.0040465.g001

Figure 2. The effect of estrogen on hepcidin expression in HepG2 cells. (A) E2 treatment upregulated hepcidin expression in a concentration-dependent manner. HepG2 cells were treated with E2 for 24 h. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=4–8 in each group. (B) E2-induced hepcidin expression was not abolished by the ER inhibitor ICI 182720. HepG2 cells were pretreated with ICI 182720 (1 × 10⁻⁶ M) for 1 h before E2 treatment. Subsequently, the cells were treated with E2 (1 × 10⁻⁷ M) or vehicle for 24 h. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=4 in each group. (C) E2 and ICI 182780 increased hepcidin expression in HuH-7 cells. HuH-7 cells were pretreated with ICI 182720 (1 × 10⁻⁶ M) for 1 h before E2 treatment. Subsequently, the cells were treated with E2 (1 × 10⁻⁷ M) or vehicle for 24 h. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=5 in each group.

doi:10.1371/journal.pone.0040465.g002

Figure 3. Silencing of GPR30 reduced E2-induced hepcidin expression in HepG2 cells. (A) HepG2 cells were transfected with 40 nM GPR30 siRNA. GPR30 mRNA levels were reduced after treatment with GPR30 siRNA; n=4 in each group. (B) Treatment with GPR30 siRNA suppressed E2-induced hepcidin upregulation in HepG2 cells. Forty-eight hours after siRNA transfection, HepG2 cells were treated with E2 (1 × 10⁻⁷ M) or vehicle for 24 h; n=10 in each group. (C) Treatment with GPR30 siRNA decreased ICI 182720-induced hepcidin upregulation in HepG2 cells. Forty-eight hours after siRNA transfection, HepG2 cells were treated with ICI 182720 (1 × 10⁻⁶ M) or vehicle for 24 h; n=4 in each group. (D) The effect of the GPR30 antagonist G1 in HepG2 cells. G1 upregulated hepcidin expression in HepG2 cells in a concentration-dependent manner. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n=4–8 in each group.

doi:10.1371/journal.pone.0040465.g003
serum and liver iron levels were elevated in this study. Some studies have shown that hepatic hepcidin expression is reduced in hepatitis C mice with elevated serum and liver iron content [17], while serum hepcidin levels were increased in patients with hepatitis C [18], which are similar to the results obtained in our study. In addition, serum hepcidin levels correlated with serum iron levels, but not with mRNA levels of hepcidin in the livers of patients with hepatocellular cancer [19]. Thus, the relationship between hepatic hepcidin expression and the serum hepcidin concentration under some clinical conditions remains controversial. Further studies are necessary to clarify this discrepancy between hepatic hepcidin expression and serum hepcidin levels.

In the present study, we demonstrated that estrogen is potentially involved in the regulation of iron absorption via the coordination of hepatic hepcidin and duodenal FPN. However, there is a gender discrepancy between humans and mice with respect to iron metabolism and hepcidin regulation. Body iron content is typically lower in women than in men, whereas several studies on mice have shown that female mice have higher iron content in the liver and spleen than male mice [20,21]. Females menstruate monthly from adolescence until menopause in humans but not in mice. Regarding the relationship between hepcidin and gender-specific differences in iron storage, hepatic hepcidin expression is higher in female mice than in male mice [20,21]. In contrast, recent clinical studies have shown that serum hepcidin

Figure 4. BMP6 signaling is involved in estrogen-induced hepcidin expression via GPR30 in HepG2 cells. (A) Effects of E2 (1 x 10^-7 M), ICI 182720 (1 x 10^-6 M), and G1 (1 x 10^-8 M) on BMP6 expression in HepG2 cells. HepG2 cells were incubated for 24 h with each reagent; n = 10 in each group. (B) E2-induced upregulation of BMP6 expression was inhibited by GPR30 silencing in HepG2 cells. Forty-eight hours after GPR30 siRNA transfection, HepG2 cells were treated with E2 (1 x 10^-7 M) or vehicle for 24 h; n = 8 in each group. (C) BMP6 silencing decreased hepcidin expression in HepG2 cells. Left panel: HepG2 cells transfected with 40 nM BMP6 siRNA. BMP6 mRNA levels were reduced after treatment with BMP6 siRNA. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n = 4 in each group. Right panel: Treatment with BMP6 siRNA decreased hepcidin expression in HepG2 cells. Hepcidin downregulation induced by BMP6 silencing was not restored by E2 treatment. Values are expressed as mean ± SEM; *P<0.05, **P<0.01, n = 8 in each group. doi:10.1371/journal.pone.0040465.g004
levels are lower in women than in men [22], and premenopausal women have lower serum hepcidin concentrations than postmenopausal women [23,24]. Thus, it is difficult to apply our results regarding the effects of estrogen on hepcidin expression to humans.

Although the effects of the relationship between estrogen and hepcidin on iron metabolism remains unclear, testosterone has been demonstrated to participate in iron metabolism via hepcidin. Testosterone administration decreases serum hepcidin concentrations [25]. Women with polycystic ovary syndrome, who have decreased estrogen and increased testosterone levels, also show reduced serum hepcidin levels [26]. In this study, we showed the effects of estrogen on hepcidin expression. Therefore, further study is necessary to determine the mechanisms of action of sex steroid hormones in regulating hepcidin expression as well as iron metabolism.
In conclusion, estrogen regulates iron absorption via hepcidin in the liver. The effects of estrogen on hepcidin expression are exerted through a GPR30-BMP6-dependent mechanism. Estrogen-deficient conditions after ovariectomy resulted in augmented iron absorption in the duodenum because of the downregulation of hepcidin in the liver and contributed to increased body iron storage. Excess iron content is known to cause oxidative stress via the Haber-Weiss reaction [27]. These findings regarding the effects of estrogen on iron metabolism might explain the increase in iron accumulation in estrogen-deficient conditions such as menopausal disorders.

**Materials and Methods**

**Materials**

We purchased 17ß-estradiol (E2), ICI 182780, and the GPR30 agonist G1 from Calbiochem (San Diego, CA), Tocris Bioscience (Ellisville, MO), and Cayman Chemical Company (Ann Arbor, MI), respectively. The following commercially available antibodies were used: anti-FPN (Alpha Diagnostics, San Antonio, TX), anti-BMP6 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-hepcidin (Abcam, Tokyo, Japan), and anti-ß-actin as a loading control (Cell Signaling Technology, Beverly, MA).
Animal Preparation and Ovariectomy

All experimental procedures were performed in accordance with the guidelines of the Animal Research Committee of the University of Tokushima Graduate School, and protocols were approved by the Institutional Review Board for Animal protection. Six-week-old female C57/Bl6j mice were purchased from Nippon CLEA (Tokyo, Japan). The mice were maintained with free access to water and food (Type NMF; Oriental Yeast, Tokyo, Japan). The iron concentration of the food was 0.01%. Before the experiments, mice were randomly divided into 2 groups: ovariectomized (OVX) and sham-operated groups. The bilateral ovariectomy procedure was performed as follows. In brief, the mice were anesthetized by peritoneal injection of 20 mg·kg⁻¹ pentobarbital. Next, 2 lateral incisions were made in the skin and the muscle layer. The ovaries were extracted through the incision and excised after ligation. Tissue samples were collected 3 months after the operation. In an additional experiment, OVX mice were administered E2 or G1 via an osmotic mini-pump during the final 24 h. For all the experiments, transfected HepG2 cells were used 48 h after transfection. The siRNA sequences were as follows: sense strand 5'-CUGACACCGUGCCCAAAGATT-3' and antisense strand 5'-UCGGUGUCGACGGUGUGCTTT-3' for GPR30 siRNA; sense strand 5'-CAGAAUUCCGCAUCUAAATT-3' and antisense strand 5'-UUGUAGAUGCGGAUUUCUGTTT-3' for BMP6 siRNA.

Small Interfering RNA (siRNA) Experiments

siRNAs targeting human GPR30 and BMP6 and a non-targeting siRNA control sequence were purchased from Sigma-Aldrich (Tokyo, Japan), and transfection was performed as previously reported [33]. Briefly, subconfluent HepG2 cells were transfected for 24 h with 40 nM of each siRNA by using Lipofectamine™ RNAiMAX in Opti-MEM medium (Life Technologies Japan Ltd.) according to the manufacturer’s instruction. Next, the conditioned medium was replaced with fresh serum-free DMEM, after which the cells were incubated for 24 h. For all the experiments, transfected HepG2 cells were used 48 h after transfection. Protein Extraction and Western Blot Analysis

Three months after ovariectomy, the liver and duodenum were removed and stored at −80°C until use. Hepatoma cells were washed with PBS, scraped, and stored at −80°C until further use. Protein preparation and western blotting were performed as previously described [34]. In brief, tissues or cells were homogenized, and proteins were extracted. Extracted proteins were boiled for 5 min in Laemmli sample buffer and then separated using SDS-PAGE. Once the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane, the membrane was blocked for 1 h at room temperature. Next, the membrane was incubated individually with each primary antibody overnight at 4°C, followed by incubation for 1 h with the respective secondary antibody. Immunoreactive bands were detected using a chemiluminescence reagent. Densitometry of the visualized bands was quantified using Image J 1.30× software.

Immunohistochemistry

Duodenal samples extracted from mice were fixed in 4% paraformaldehyde at 4°C overnight and then embedded in paraffin. Samples were cut into 2-μm sections and deparaffinized. After antigen retrieval with 10 mM citrate buffer at 95°C for 10 min, sections were incubated in primary antibody at 4°C overnight. Staining was visualized by a linked streptavidin-biotin complex assay and a DAB substrate kit (LSAB+ Kit Universal; Dako Japan, Tokyo, Japan). The negative control was incubated without the primary antibody.

Measurement of Tissue and Serum Iron Concentration

Tissue iron concentration and serum iron levels were measured using an iron assay kit according to the manufacturer’s instructions (Metallo assay, AKJ Global Technology Co., Ltd., Chiba, Japan). In brief, the extracted liver tissues were weighted and homogenized in cell lysis buffer. The crude lysates were further dissolved using an ultrasonic sonicator. Hydrochloric acid (6 N) was added
to the samples at a final concentration of 0.05 M; samples were then mixed well and incubated at room temperature for 30 min. Following centrifugation, the supernatants were used for measurements. Tissue iron concentration was corrected using the tissue weight and is expressed as ng g⁻¹ tissue.

**Measurement of Serum Hepcidin Levels**

Serum mouse hepcidin-1 concentrations were quantitatively analyzed by SELDI-TOF mass-spectrometry as described previously [35]. The assay was performed by Medical Care Proteomics Biotechnology Co., Ltd. (Kanazawa, Japan).

**Statistical Analysis**

Data are presented as mean ± standard error of mean (SEM). An unpaired, 2-tailed Student’s t-test was used for comparison between 2 groups. For comparisons between more than 2 groups, the statistical significance of each difference was evaluated by post-hoc test using Dunnett’s method or Tukey-Kramer’s method. Statistical significance was indicated by P<0.05.

**Author Contributions**

Conceived and designed the experiments: YI S. Tajima TT. Performed the experiments: YI S. Tajima. Analyzed the data: YI S. Tajima YI YK KI S. Tomita KT TT. Contributed reagents/materials/analysis tools: YI S.Tajima YI-I YK KI S. Tomita. Wrote the paper: YK.

**References**

1. Milman N (1996) Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int J Hematol 63: 103–135.
2. Jia J, Pelle E, Huang X (2009) Iron and mononuclear does increased iron affect the health of postmenopausal women? Antioxid Redox Signal 11: 2929–2943.
3. Björnström L, Syöjä M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19: 833–842.
4. Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26: 323–342.
5. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090–2093.
6. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, et al. (2009) BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41: 482–487.
7. Meynard D, Kautz L, Darmaud V, Canonne-Hergaux F, Coppin H, et al. (2009) Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41: 478–481.
8. Nemeth E, Rivera S, Gahavan Y, Keller C, Taurour S, et al. (2004) IL-6 mediates hypofeberremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271–1276.
9. Prossnitz ER, Arterburn JR, Sklar LA (2007) GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 265–266: 138–142.
10. Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146: 624–632.
11. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806–7810.
12. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, et al. (2000) LEAP-1, stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 98: 8780–8785.
13. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, et al. (2005) The iron exporter ferroportin/Skp01a is essential for iron homeostasis. Cell Metab 1: 191–200.
14. Nicolais G, Bennoun M, Deya I, Beaumont C, Grandchamp B, et al. (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USP2) knockout mice. Proc Natl Acad Sci U S A 98: 8780–8785.
15. Viatte L, Lesbores-Brion JC, Lou DQ, Bennoun M, Nicolais G, et al. (2005) Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 105: 4361–4368.
16. Bekri S, Gual P, Anty R, Luciani N, Dahman M, et al. (2006) Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131: 788–796.
17. Nishina S, Hino K, Kornaga M, Vecchi C, Pietrangelo A, et al. (2008) Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134: 226–239.
18. Floriani A, Navaglia F, Rizzotto ER, Basso D, Chiaramonte M, et al. (2011) Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload. Clin Chem Lab Med 49: 197–206.

PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e40465

Effects of Estrogen on Hepcidin Expression

19. Kijima H, Sawada T, Tomougi N, Kubota K (2008) Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 8: 167.
20. Coureuil B, Tresac AB, Fruchon S, Ilyin G, Borot N, et al. (2004) Strain and gender modulate hepatic hepcidin 1 and 2 mRNA expression in mice. Blood Cells Mol Dis 32: 283–289.
21. Krijt J, Cinekova R, Sykorova V, Vokac M, Vysoral D, et al. (2004) Different expression pattern of hepcidin genes in the liver and pancreas of C57BL/6J and DBA/2J mice. J Hepatol 40: 891–896.
22. Ganz T, Olhina G, Girelli D, Nemeth E, Westerman M (2000) Immunnoassay for human serum hepcidin. Blood 112: 4292–4297.
23. Galesdot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroon JJ, et al. (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117: e218–223.
24. Blesener O, Parkkainen J, Steuman UE, Hamalainen E (2011) Preanalytical factors and reference intervals for serum hepcidin LC/MS/MS method. Clin Chim Acta.
25. Bachman E, Feng R, Trazion T, Li M, Olhina G, et al. (2010) Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab 95: 4743–4747.
26. Lapre-Ramirez M, Alvarez-Blasco F, Alpanes M, Escobar-Morreale HF (2011) Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J Clin Endocrinol Metab 96: 846–852.
27. Krueszewski M (2003) Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531: 81–92.
28. Osako MK, Nakagami H, Kobuchi N, Shimizu H, Nakagami F, et al. (2010) Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 107: 466–473.
29. Wang C, Dehghani B, Li Y, Kaler LJ, Proctor T, et al. (2009) Membrane estrogen receptor regulator regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 182: 3304–3303.
30. Solakidi S, Psarra AM, Sekeris CE (2007) Differential distribution of glucocorticoid and estrogen receptor isoforms: localization of GRbeta and ERalpha in nucleoli and GRalpha and ERbeta in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines. J Musculoskelet Neuronal Interact 7: 240–245.
31. Marino M, Distefano E, Trentalange A, Smith CL (2001) Estradiol-induced IP3 mediates the estrogen receptor activity expressed in human cells. Mol Cell Endocrinol 182: 19–26.
32. Cheng X, Shimizu I, Yuan Y, Wei M, Shen M, et al. (2006) Effects of estradiol and progesterone on tumor necrosis factor alpha-induced apoptosis in human hepatoma Huh-7 cells. Life Sci 79: 1989–1994.
33. Ikeda Y, Tajima S, Yoshida S, Yamano N, Kihira Y, et al. (2011) Deferoxamine receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 24: 1338–1348.
34. Ikeda Y, Tajima S, Yoshida S, Yamano N, Kihira Y, et al. (2011) Deferoxamine receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 24: 1338–1348.
35. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, et al. (2006) Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108: 1381–1387.